[go: up one dir, main page]

CY1125181T1 - Ανοσοσυζευγματα που στοχευουν adam9 και μεθοδοι χρησης αυτων - Google Patents

Ανοσοσυζευγματα που στοχευουν adam9 και μεθοδοι χρησης αυτων

Info

Publication number
CY1125181T1
CY1125181T1 CY20221100306T CY221100306T CY1125181T1 CY 1125181 T1 CY1125181 T1 CY 1125181T1 CY 20221100306 T CY20221100306 T CY 20221100306T CY 221100306 T CY221100306 T CY 221100306T CY 1125181 T1 CY1125181 T1 CY 1125181T1
Authority
CY
Cyprus
Prior art keywords
immunoconjugates
adam9
relates
methods
immunoconductions
Prior art date
Application number
CY20221100306T
Other languages
English (en)
Inventor
Stuart William HICKS
Nicholas C. Yoder
Bhaswati Barat
Ezio Bonvini
Gundo Diedrich
Leslie S. Johnson
Deryk Loo
Juniper A. SCRIBNER
Original Assignee
Macrogenics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics, Inc. filed Critical Macrogenics, Inc.
Publication of CY1125181T1 publication Critical patent/CY1125181T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αφορά ανοσοσυζεύγματα που περιλαμβάνουν ένα αντίσωμα ή θραύσμα αυτού ικανό να δεσμεύεται ειδικά με την Πρωτεΐνη «ADAM9» («Disintegrin and Metalloproteinase Domain-containing Protein 9») συζευγμένη με τουλάχιστον έναν φαρμακολογικό παράγοντα. Η εφεύρεση αφορά συγκεκριμένα τέτοια ανοσοσυζεύγματα που είναι διασταυρούμενα δραστικά με ανθρώπινη ADAM9 και την ADAM9 ενός μη ανθρώπινου πρωτεύοντος (π.χ. ενός πιθήκου cynomolgus). Η εφεύρεση επιπλέον αφορά όλα αυτά τα ανοσοσυζεύγματα που περιλαμβάνουν μία Μεταβλητή Επικράτεια Ελαφράς Αλυσίδας (VL) και/ή μία Μεταβλητή Επικράτεια Βαριάς Αλυσίδας (VH) που έχει ανθρωποποιηθεί και/ή αποανοσοποιηθεί έτσι ώστε να επιδεικνύει μειωμένη ανοσογονικότητα κατά τη χορήγηση αυτού του ανοσοσυζεύγματος σε ένα υποκείμενο δέκτη. Η εφεύρεση αφορά επίσης φαρμακευτικές συνθέσεις οι οποίες περιέχουν οποιοδήποτε από τέτοια ανοσοσυζεύγματα, και μεθόδους που περιλαμβάνουν τη χρήση οποιωνδήποτε τέτοιων ανοσοσυζευγμάτων στη θεραπεία του καρκίνου και άλλων νόσων και καταστάσεων.
CY20221100306T 2016-12-23 2022-04-27 Ανοσοσυζευγματα που στοχευουν adam9 και μεθοδοι χρησης αυτων CY1125181T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662438488P 2016-12-23 2016-12-23
US201762480201P 2017-03-31 2017-03-31

Publications (1)

Publication Number Publication Date
CY1125181T1 true CY1125181T1 (el) 2024-12-13

Family

ID=61025051

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20221100306T CY1125181T1 (el) 2016-12-23 2022-04-27 Ανοσοσυζευγματα που στοχευουν adam9 και μεθοδοι χρησης αυτων

Country Status (18)

Country Link
US (1) US20210388102A1 (el)
EP (1) EP3558391B1 (el)
JP (1) JP7170642B2 (el)
CN (1) CN110267685B (el)
CY (1) CY1125181T1 (el)
DK (1) DK3558391T3 (el)
ES (1) ES2912266T3 (el)
HR (1) HRP20220550T1 (el)
HU (1) HUE058664T2 (el)
LT (1) LT3558391T (el)
MD (1) MD3558391T2 (el)
PL (1) PL3558391T3 (el)
PT (1) PT3558391T (el)
RS (1) RS63154B1 (el)
SI (1) SI3558391T1 (el)
SM (1) SMT202200182T1 (el)
TW (1) TWI783957B (el)
WO (1) WO2018119196A1 (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7474195B2 (ja) 2018-01-12 2024-04-24 イミュノジェン， インコーポレイテッド 抗体薬物のコンジュゲーション、精製、及び製剤のための方法
US20210275685A1 (en) * 2018-06-26 2021-09-09 Immunogen, Inc. Immunoconjugates targeting adam9 and methods of use thereof
US11833214B2 (en) 2019-03-21 2023-12-05 Immunogen, Inc. Methods of preparing cell-binding agent-drug conjugates
KR20220010481A (ko) 2019-03-29 2022-01-25 이뮤노젠 아이엔씨 비정상 세포 성장의 억제 또는 증식성 질환의 치료를 위한 세포독성 비스-벤조디아제핀 유도체 및 세포결합제와 이의 접합체
CN113766954B (zh) 2019-04-26 2024-09-24 伊缪诺金公司 喜树碱衍生物
CN110713983B (zh) * 2019-11-04 2022-06-10 深圳市体内生物医药科技有限公司 一种表达透明质酸酶的免疫细胞及其应用
WO2022192134A1 (en) 2021-03-08 2022-09-15 Immunogen, Inc. Methods for increasing efficacy of immunoconjugates targeting adam9 for the treatment of cancer
TW202438113A (zh) * 2023-03-24 2024-10-01 大陸商映恩生物製藥（蘇州）有限公司 標靶ａｄａｍ９的人源化抗體、其抗體藥物偶聯物及其應用
WO2025094146A1 (en) 2023-11-02 2025-05-08 Immunogen Switzerland Gmbh Vasconstrictors for reducing ocular toxicity of antibody-maytansinoid conjugates

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
AU4314801A (en) 2000-02-11 2001-08-20 Lexigen Pharm Corp Enhancing the circulating half-life of antibody-based fusion proteins
US20030091568A1 (en) 2000-04-07 2003-05-15 Jurgen Frey Inhibitors for the formation of soluble human CD23
EP1142910A1 (en) 2000-04-07 2001-10-10 Jürgen Prof. Dr. Frey Inhibitors for the formation of soluble human CD23
DE60143544D1 (de) 2000-12-12 2011-01-05 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
CA2470763A1 (en) 2001-12-18 2003-06-26 Mondobiotech Laboratories Anstalt Novel pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US20040092466A1 (en) 2002-11-11 2004-05-13 Isis Pharmaceuticals Inc. Modulation of ADAM9 expression
JP2006500364A (ja) 2002-08-16 2006-01-05 イムノージェン インコーポレーテッド 高い反応性と溶解度を有する架橋剤および小分子薬物の標的化送達用コンジュゲートの調製におけるそれらの使用
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
DE10337368A1 (de) * 2003-08-08 2005-03-03 Technische Universität Dresden Verfahren und Mittel zur Diagnose und Behandlung von Pankreastumoren
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
WO2005091823A2 (en) 2004-03-01 2005-10-06 The Regents Of The University Of California The use of lunasin peptide as a transcriptional activator to prevent cancer and related methods for treatment, monitoring and prognosis
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
EP1841794B1 (en) 2005-02-02 2013-11-20 MacroGenics West, Inc. Adam-9 modulators
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
SG172656A1 (en) 2006-05-30 2011-07-28 Genentech Inc Antibodies and immunoconjugates and uses therefor
WO2007143752A2 (en) 2006-06-09 2007-12-13 The Regents Of The University Of California Targets in breast cancer for prognosis or therapy
KR101443214B1 (ko) 2007-01-09 2014-09-24 삼성전자주식회사 폐암 환자 또는 폐암 치료를 받은 폐암 환자의 폐암 재발 위험을 진단하기 위한 조성물, 키트 및 마이크로어레이
PT2019104E (pt) 2007-07-19 2013-12-03 Sanofi Sa Agentes citotóxicos compreendendo novos derivados de tomaimicina e sua utilização terapêutica
GB2453589A (en) 2007-10-12 2009-04-15 King S College London Protease inhibition
US8101361B2 (en) 2008-03-10 2012-01-24 National Jewish Health Markers for diagnosis of pulmonary inflammation and methods related thereto
JP2011516081A (ja) 2008-04-07 2011-05-26 ザイモジェネティクス， インコーポレイテッド トロンビンアクチベーター組成物ならびにそれを作製および使用する方法
US20090285840A1 (en) 2008-04-29 2009-11-19 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Methods for treating pathological neovascularization
AU2009243009B2 (en) 2008-04-30 2014-09-11 Immunogen, Inc Potent conjugates and hydrophilic linkers
WO2009134977A1 (en) 2008-04-30 2009-11-05 Immunogen, Inc. Cross-linkers and their uses
EP2282770B1 (en) 2008-06-04 2018-03-07 MacroGenics, Inc. Antibodies with altered binding to fcrn and methods of using same
US20110129450A1 (en) 2008-08-01 2011-06-02 Orly Lazarov Method of promoting neurogenesis by modulating secretase activities
GB0819095D0 (en) 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines
WO2010053539A2 (en) 2008-11-05 2010-05-14 The Texas A&M University System Methods for detecting colorectal diseases and disorders
JP2012510821A (ja) 2008-12-04 2012-05-17 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリンおよびその使用
SG2014009138A (en) 2009-02-05 2014-03-28 Immunogen Inc Novel benzodiazepine derivatives
RU2595424C2 (ru) 2009-06-03 2016-08-27 Иммьюноджен, Инк. Способы конъюгации
US20130045244A1 (en) 2010-02-11 2013-02-21 University Of Southern California Modified adam disintegrin domain polypeptides and uses thereof
MA34062B1 (fr) 2010-03-04 2013-03-05 Macrogenics Inc Anticorps réagissant avec b7-h3, fragments immunologiquement actifs associés et utilisations associées
CN102971329B (zh) 2010-04-15 2016-06-29 麦迪穆有限责任公司 用于治疗增殖性疾病的吡咯并苯并二氮杂卓
EP3666289A1 (en) 2011-02-15 2020-06-17 ImmunoGen, Inc. Cytotoxic benzodiazepine derivatives
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
WO2013049704A2 (en) 2011-09-28 2013-04-04 Armune Biosciences, Inc. Method and system of particle-phage epitope complex
WO2013098797A2 (en) 2011-12-31 2013-07-04 Kuriakose Moni Abraham Diagnostic tests for predicting prognosis, recurrence, resistance or sensitivity to therapy and metastatic status in cancer
US9534058B2 (en) 2012-02-08 2017-01-03 Abbvie Stemcentrx Llc Anti-CD324 monoclonal antibodies and uses thereof
WO2013177481A1 (en) 2012-05-25 2013-11-28 Immunogen, Inc. Benzodiazepines and conjugates thereof
WO2014108480A1 (en) 2013-01-09 2014-07-17 Friedrich-Alexander-Universitaet Erlangen-Nuernberg Method for in vitro detection and monitoring of a disease by measuring disease-associated protease activity in extracellular vesicles
EP2954056A4 (en) 2013-02-08 2016-09-21 Stemcentrx Inc NEW MULTISPECIFIC CONSTRUCTIONS
US20160024582A1 (en) 2013-04-08 2016-01-28 Mitsubishi Rayon Co., Ltd. Microarray for evaluating eye disease, and evaluation method of eye disease
WO2014186364A2 (en) 2013-05-13 2014-11-20 Tufts University Methods and compositions for prognosis, diagnosis and treatment of adam8-expressing cancer
CA2915823A1 (en) 2013-06-19 2014-12-24 Memorial Sloan-Kettering Cancer Center Methods and compositions for the diagnosis, prognosis and treatment of brain metastasis
US9567641B2 (en) 2013-07-03 2017-02-14 Samsung Electronics Co., Ltd. Combination therapy for the treatment of cancer using an anti-C-met antibody
MA40415A (fr) * 2014-09-03 2016-03-10 Immunogen Inc Conjugués comprenant des agents de liaison cellulaire et des agents cytotoxiques
KR102632830B1 (ko) 2014-09-03 2024-02-02 이뮤노젠 아이엔씨 세포독성 벤조다이아제핀 유도체
US9381256B2 (en) 2014-09-03 2016-07-05 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
AU2015346330A1 (en) 2014-11-11 2017-05-11 Amunix Operating Inc. Targeted XTEN conjugate compositions and methods of making same
MA42250B1 (fr) 2015-06-29 2020-11-30 Immunogen Inc Conjugués d'anticorps à cystéine modifiée

Also Published As

Publication number Publication date
TWI783957B (zh) 2022-11-21
JP2020504607A (ja) 2020-02-13
HUE058664T2 (hu) 2022-09-28
PL3558391T3 (pl) 2022-05-16
RS63154B1 (sr) 2022-05-31
WO2018119196A8 (en) 2019-06-20
SI3558391T1 (sl) 2022-06-30
US20210388102A1 (en) 2021-12-16
SMT202200182T1 (it) 2022-05-12
EP3558391A1 (en) 2019-10-30
MD3558391T2 (ro) 2022-05-31
JP7170642B2 (ja) 2022-11-14
CN110267685A (zh) 2019-09-20
EP3558391B1 (en) 2022-02-02
LT3558391T (lt) 2022-07-11
DK3558391T3 (da) 2022-05-09
ES2912266T3 (es) 2022-05-25
WO2018119196A1 (en) 2018-06-28
CN110267685B (zh) 2023-06-20
HRP20220550T1 (hr) 2022-06-10
PT3558391T (pt) 2022-05-05
TW201822821A (zh) 2018-07-01

Similar Documents

Publication Publication Date Title
CY1125181T1 (el) Ανοσοσυζευγματα που στοχευουν adam9 και μεθοδοι χρησης αυτων
PE20190353A1 (es) Moleculas de union b7-h3 novedosas, conjugados anticuerpo-farmaco de los mismos y metodos de uso de los mismos
CY1123525T1 (el) Μορια δεσμευσης ειδικα για asct2 και χρησεις αυτων
CY1122472T1 (el) Συζευγμα-αντισωματος-φαρμακου και η χρηση αυτου για την αγωγη του καρκινου
CY1121517T1 (el) Μη φουκοζυλιωμενα αντισωματα enanti-fgfr2iiib
CY1124628T1 (el) Συζευγματα αντισωματος-φαρμακου βασει εριβουλινης και μεθοδοι χρησεως
CY1121949T1 (el) Φαρμακοτεχνικες μορφες συζευγματος anti-egfr αντισωματος-φαρμακου
CY1123783T1 (el) Antiσωμαta enanti-b7-h3 και συζευγματα αντισωματος φαρμακου
CY1124435T1 (el) Νουκλεικα οξεα που κωδικοποιουν ανθρωπινα αντισωματα σε sialyl-lewis α
CL2020000263A1 (es) Conjugado de anticuerpo monoclonal contra bcma-fármaco.
EA201800444A1 (ru) Производные майтанзиноида, их конъюгаты и способы использования
CY1121783T1 (el) Συζευγμα αντισωματος-igf-1r-φαρμακου και η χρηση αυτου για την αγωγη του καρκινου
EA201692530A1 (ru) Цитотоксические пептиды и их конъюгаты
PE20170912A1 (es) Conjugados de anticuerpo-farmaco
EA202091161A1 (ru) Конъюгаты антител против cd22 с майтанзином, их комбинации и способы применения
EA201792300A1 (ru) Комбинации иммуноконъюгата к cd37 и антитела к cd20
EA201691251A1 (ru) Цитотоксические пептиды и их конъюгаты
EA201992595A1 (ru) Усиление фармакокинетики бифункциональных хелатов и их применения
MX2020013466A (es) Inmunoconjugados dirigidos a adam9 y métodos para usarlos.
PE20151672A1 (es) Anticuerpos e inmunoconjugados anti-b7-h4
EA201900562A1 (ru) Бис-октагидрофенантрена карбоксамиды и их белковые конъюгаты
CU24644B1 (es) Conjugados anticuerpo-fármaco para ablación de células madre hematopoyéticas
EA202191769A1 (ru) Тубулизины и конъюгаты белок-тубулизин
SA520412283B1 (ar) Cd22 أجسام مضادة ذات سلسلة ثقيلة ترتبط بـ
MX2017012615A (es) Anticuerpo anti-notch4 humano.